Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Thermo Fisher Scientific (NY: TMO )

516.18 -12.66 (-2.39%)
Official Closing Price Updated: 4:00 PM EST, Dec 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Thermo Fisher Scientific

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 10 Years
Via Benzinga
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
Mainz Biomed partners with Thermo Fisher to develop advanced colorectal cancer screening tools while enhancing ColoAlert for faster, accurate results. 
Via Benzinga
How Is The Market Feeling About Thermo Fisher Scientific?
Via Benzinga
Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test
Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test 
Via News Direct
Check Out What Whales Are Doing With TMO
Via Benzinga
The Oncology Bet Is Already Paying Off For Pfizer
With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14%... 
Via Benzinga
Exposures COVID-19
Market Whales and Their Recent Bets on TMO Options
Via Benzinga
Earnings Outlook For Thermo Fisher Scientific
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
Via Benzinga
Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening
Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening 
Via News Direct
Here's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today
Via Benzinga
Tradepulse Power Inflow Alert: Thermo Fisher Scientific Inc. Climbs Over 9 Points On Session After Alert
Via Benzinga
Thermo Fisher Scientific (TMO) Q3 2024 Earnings Call Transcript
TMO earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Thermo Fisher Scientific Sails Through Q3 With Mixed Earnings, CEO Says In Great Position To Deliver 2024 Objectives
Thermo Fisher Scientific's Q3 revenue of $10.59 billion missed expectations. Adjusted EPS beat estimates but dropped year-over-year. Guidance for 2024 remains reaffirmed. 
Via Benzinga
(TMO) - Analyzing Thermo Fisher Scientific's Short Interest
Via Benzinga
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,000 Today
Via Benzinga
Is NYSE:TMO suited for quality investing?
Analyzing the Quality Characteristics of THERMO FISHER SCIENTIFIC INC (NYSE:TMO). 
Via Chartmill
Wall Street Slumps For Third Straight Day As Investor Sentiment Fades, Dollar Strength Resumes, Boeing Disappoints: What's Driving Markets Wednesday?
Wall Street is on track for its third consecutive day of losses as investors grow cautious about risky assets, awaiting more clarity on U.S. fiscal and monetary policies and scrutinizing the latest... 
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. 
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $13,000 Today
Via Benzinga
Spotlight on Thermo Fisher Scientific: Analyzing the Surge in Options Activity
Via Benzinga
Looking Into Thermo Fisher Scientific's Recent Short Interest
Via Benzinga
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization... 
Via Benzinga
Exposures Product Safety
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Industry Leader Thermo Fisher's Contract Services Positioned For Growth Amid Popular Demand For GLP-1 Weight Loss Drugs, Analyst Initiates With Long-Term Growth Potential
Stephens initiated coverage on Thermo Fisher Scientific with an Overweight rating and $680 price target. The firm highlights the company's biopharma expansion, M&A strategy, and key growth areas like... 
Via Benzinga
Momentum Investing Gives You An Edge, Until It Doesn’t
Since 2020, momentum investing has generated significantly better returns than other strategies. Such is not surprising, given the massive amounts of stimulus injected into the financial system. 
Via Talk Markets
Thermo Fisher Scientific Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
Via Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
$100 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.